In this work we couple a physiologically based mathematical model of integrated calcium and phosphorus homeostasis to a cell population bone remodelling model and to a pharmacokinetics (PK) - pharmacodynamics (PD) model of denosumab (Dmab), an antiresorptive drug administered to combat osteoporosis (OP). The model of Ca and P homeostasis allows to incorporate the effect of factors such as Ca dietary changes, vitamin D supplementation, concurrence of renal deficiency or hyperparathyroidism into the study of OP and its treatment.
Published on 02/11/23
Submitted on 02/11/23
Volume Multiscale and coupled problems in bioengineering, 2023
DOI: 10.23967/c.coupled.2023.019
Licence: CC BY-NC-SA license
Are you one of the authors of this document?